Protalix BioTherapeutics (DE) (PLX) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) is the larger company by market cap ($244.5 million vs $228.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLX | SCTX |
|---|---|---|
| Share price | $2.90 | $12.07 |
| Market cap | $244.52M | $228.58M |
| 1-day change | -5.23% | -8.70% |
| YTD return | +61.11% | — |
| 1-year return | +65.71% | — |
| 5-year return | +192.93% | — |
| P/E ratio (TTM) | 12.08 | — |
| Forward P/E | 4.68 | — |
| EPS (TTM) | $0.24 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $52.74M | — |
| Revenue growth (YoY) | -1.23% | — |
| Net income (latest FY) | $-6.60M | — |
| Gross margin | 48.82% | — |
| Operating margin | -10.43% | — |
| Net margin | -12.52% | — |
| 52-week high | $3.19 | $39.60 |
| 52-week low | $1.65 | $12.00 |
| Distance from 52-week high | -9.09% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +313.79% | +372.25% |
| Average volume | 903.48K | 403.27K |
| Shares outstanding | 84.32M | 18.94M |
| Employees | 226 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
PLX vs SCTX FAQ
Which is bigger, Protalix BioTherapeutics (DE) or Scribe Therapeutics?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $244.52M compared with $228.58M for Scribe Therapeutics (SCTX).
Are Protalix BioTherapeutics (DE) and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.